Alseres CEO notes molecular-imaging candidate is in Phase III studies

06/12/2008 | PharmaLive.com

Alseres Pharmaceuticals' lead molecular-imaging candidate, Altropane, is in two-part Phase III clinical trials to test its diagnostic efficacy in Parkinson's disease patients with tremor, according to the company chairman and CEO's annual letter to stockholders.

View Full Article in:

PharmaLive.com

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
NGS Provider Enrollment Rep
National Government Services - WellPoint
Harrisburg, PA
Program Manager II
Tufts Health Plan/Network Health
Medford, MA
Director, Medicare Advantage/Medicare Part D Focus
Avalere Health
Washington, DC
Chief, Product Review Branch
FDA/Center for Biologics Evaluation and Research
Silver Spring, MD
Director of Clinical Research
Regenesis Biomedical, Inc.
Scottsdale, AZ